Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
MetadataShow full item record
Because of the lack of significant disease-modifying drugs for neurodegenerative disorders, a pressing need for new chemical entities endowed with IMAO-B still exists. Within this framework, and for the first time, a study was performed to compare coumarin- and chomone-3-phenylcarboxamide scaffolds. Compounds 10a and 10b were the most potent, selective, and reversible noncompetitive IMAO-B. The benzopyrone sp2 oxygen atom was found to be position independent and a productive contributor for the ligand-enzyme complex stability. © 2017 American Chemical Society.
Showing items related by title, author, creator and subject.
PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor (2020) Fernandes C.; Martins C.; Fonseca A.; Nunes R.; Matos M.J.; Silva R.; Garrido J.; Sarmento B.; Remião F.; Otero-Espinar F.J.; ... (American Chemical Society, 2018)
Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors (2020) Costas-Lago M.C.; Besada P.; Rodríguez-Enríquez F.; Viña D.; Vilar S.; Uriarte E.; Borges F.; Terán C. (Elsevier Masson SAS, 2017)
3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter? (2020) Mellado M.; Mella J.; González C.; Viña D.; Uriarte E.; Matos M.J. (Academic Press Inc., 2020)